Private Wealth Asset Management LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5,909.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,863 shares of the biopharmaceutical company’s stock after buying an additional 1,832 shares during the period. Private Wealth Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $1,413,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in the company. LCM Capital Management Inc raised its stake in shares of Regeneron Pharmaceuticals by 2.2% during the third quarter. LCM Capital Management Inc now owns 616 shares of the biopharmaceutical company’s stock valued at $467,000 after acquiring an additional 13 shares during the last quarter. Oakworth Capital Inc. increased its holdings in Regeneron Pharmaceuticals by 25.0% during the 3rd quarter. Oakworth Capital Inc. now owns 70 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 14 shares during the period. Kestra Investment Management LLC increased its holdings in Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Kestra Investment Management LLC now owns 675 shares of the biopharmaceutical company’s stock valued at $512,000 after purchasing an additional 16 shares during the period. Glenview Trust Co increased its holdings in Regeneron Pharmaceuticals by 0.4% during the 3rd quarter. Glenview Trust Co now owns 4,421 shares of the biopharmaceutical company’s stock valued at $3,352,000 after purchasing an additional 17 shares during the period. Finally, Bingham Private Wealth LLC raised its position in Regeneron Pharmaceuticals by 3.7% during the 3rd quarter. Bingham Private Wealth LLC now owns 473 shares of the biopharmaceutical company’s stock valued at $359,000 after purchasing an additional 17 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms have weighed in on REGN. Royal Bank Of Canada increased their price objective on Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the stock a “sector perform” rating in a report on Monday, November 2nd. TD Cowen upped their target price on Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the company a “buy” rating in a report on Wednesday, October 21st. Robert W. Baird raised their price target on Regeneron Pharmaceuticals from $761.00 to $875.00 and gave the stock a “neutral” rating in a research note on Monday, November 2nd. BMO Capital Markets raised their price target on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. Finally, Leerink Partners lifted their price target on shares of Regeneron Pharmaceuticals from $835.00 to $997.00 and gave the company a “market perform” rating in a report on Monday, November 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $904.41.
View Our Latest Stock Analysis on REGN
Trending Headlines about Regeneron Pharmaceuticals
Here are a few of the latest headlines about REGN:
- Positive Sentiment: The FDA approved Livsayis (cemdisiran) for adults with anti-AChR-positive generalized myasthenia gravis. It is the first approved siRNA therapy for the condition and the only treatment given by subcutaneous injection just four times a year. Phase 3 results showed sustained disease control between doses, giving Regeneron a new neurology product and potential revenue source. Livsayis FDA approval announcement
- Positive Sentiment: Regeneron plans to present new hematology data at the December ASH meeting, including potentially pivotal Ordspono results in marginal zone lymphoma. The data could provide further evidence of the company’s pipeline opportunity, though it is not yet a clinical or regulatory outcome. Regeneron ASH data announcement
- Neutral Sentiment: Livsayis will compete with established treatments for generalized myasthenia gravis, so adoption and commercial performance remain important to watch despite its distinctive dosing schedule. Livsayis competitive context
Insiders Place Their Bets
In other news, Director Huda Zoghbi sold 7,439 shares of the company’s stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $970.46, for a total value of $7,219,251.94. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,652,693.38. This represents a 81.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Marion Mccourt sold 1,215 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the transaction, the executive vice president directly owned 13,134 shares in the company, valued at $11,163,900. This trade represents a 8.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 32,039 shares of company stock valued at $29,825,285. 6.97% of the stock is owned by company insiders.
Regeneron Pharmaceuticals Trading Down 0.3%
NASDAQ REGN opened at $920.69 on Friday. The firm has a market capitalization of $95.25 billion, a PE ratio of 20.33, a P/E/G ratio of 1.26 and a beta of 0.10. The stock’s 50 day moving average is $829.76 and its 200 day moving average is $752.07. Regeneron Pharmaceuticals, Inc. has a twelve month low of $591.52 and a twelve month high of $991.73. The company has a quick ratio of 2.89, a current ratio of 3.35 and a debt-to-equity ratio of 0.06.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The firm had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. During the same period in the prior year, the firm earned $11.83 EPS. The company’s revenue was up 36.3% compared to the same quarter last year. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be given a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.30%.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.
Read More
- Five stocks we like better than Regeneron Pharmaceuticals
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
